• Explore /
  • Poster
  • / Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor α (FRα)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials.

Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor α (FRα)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials.

Abstract Poster

Authors

Kathleen Moore

Kathleen N. Moore

Division of Obstetrics and Gynecology, Department of Gynecologic Oncology, University of Oklahoma Health Science Center, Stephenson Cancer Center, Oklahoma City, OK

Kathleen N. Moore , Domenica Lorusso , Ana Oaknin , Amit M. Oza , Nicoletta Colombo , Toon Van Gorp , David M. O'Malley , Susana N. Banerjee , Conleth G. Murphy , Philipp Harter , Gottfried E. Konecny , Patricia Pautier , Michael W. Method , Jiuzhou Wang , Michael J. Birrer , Robert L. Coleman , Ursula A. Matulonis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01609556, NCT04296890, NCT02631876

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5574)

DOI

10.1200/JCO.2022.40.16_suppl.5574

Abstract #

5574

Poster Bd #

450

Abstract Disclosures

Similar Posters

First Author: David M. O'Malley

First Author: Fabian Trillsch

First Author: Ursula A. Matulonis

First Author: Fabian Trillsch